effects

Hard Forks, Soft Forks, Defaults and Coercion

Source Node:
Time Stamp: February 20, 2024 1:15 PM - Modified On: February 20, 2024 - Published By:
Source Cluster:
Republished By Plato

One of the important arguments in the blockchain space is that of whether hard forks or soft forks are the preferred protocol upgrade mechanism. The basic difference between the two is that soft forks change the rules of a protocol by strictly reducing the set of transactions that is valid, so nodes following the old rules will still get on the new chain (provided that the majority of miners/validators implements the fork), whereas hard forks allow previously invalid transactions and blocks to become valid, so clients must upgrade their clients

Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies

Source Node:
Time Stamp: February 7, 2024 10:49 AM - Modified On: February 7, 2024 - Published By:
Source Cluster:
Republished By Plato

Legislation Puts Renewed Focus on Next-Generation NK Cell Therapies New York, Feb 7, 2024 - (Plato Data) - On Thursday February 2, 2024, the bio industry welcomed the parliament’s passage of a bill that adds regenerative medicine organizations to the list of those considered for human cell management business licenses. The National Assembly passed the “Amendment to the Act on Safety and Support for Advanced Regenerative Medicine and Advanced Biopharmaceuticals” in a plenary session paving the way for certain next generation NK Cell Therapy companies to recognized as a licensed

Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries

Source Node:
Time Stamp: February 2, 2024 2:30 PM - Modified On: February 2, 2024 - Published By:
Source Cluster:
Republished By Plato

  New York, Feb 2, 2024 - (Plato Data)- Fortress Biotech (Fortress Bio), a unique biotech company led by industry veteran Dr. Lindsay Rosenwald, focused on identifying, in-licensing and developing high-potential marketed drugs and development-stage drug candidates in-house and through its subsidiary partner companies, has announced multiple new milestones to start 2024 with a bang. Avenue Therapeutics Finalizes Phase 3 Study for IV Tramadol with FDA Avenue Therapeutics, a subsidiary of Fortress Bio, has reached a significant milestone in its quest to introduce new therapies for neurologic diseases. The company

A Note On Charity Through Marginal Price Discrimination

Source Node:
Time Stamp: February 2, 2024 11:16 AM - Modified On: February 2, 2024 - Published By:
Source Cluster:
Republished By Plato

Vitalik Buterin via the Vitalik Buterin Blog Updated 2018-07-28. See end note. The following is an interesting idea that I had two years ago that I personally believe has promise and could be easily implemented in the context of a blockchain ecosystem, though if desired it could certainly also be implemented with more traditional technologies (blockchains would help get the scheme network effects by putting the core logic on a more neutral platform). Suppose that you are a restaurant selling sandwiches, and you ordinarily sell sandwiches for $7.50. Why did

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

Source Node:
Time Stamp: December 29, 2023 3:07 AM - Modified On: December 29, 2023 - Published By:
Source Cluster:
Republished By Plato

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:54 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:16 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis in

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Source Node:
Time Stamp: August 29, 2023 8:16 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement

Livento Group, Inc. Announces Second Quarter Results with Revenue Growth of Over 90%, Including Significant Achievements and Updates

Source Node:
Time Stamp: August 17, 2023 3:06 PM - Modified On: August 17, 2023 - Published By:
Source Cluster:
Republished By Plato

NEW YORK, NY / August 14, 2023 / NuGene International, Inc./Livento Group, Inc. (OTC Pink:NUGN), a dynamic leader specializing in the acquisition and development of companies with disruptive business models in film, content, and technology sectors, is pleased to announce revenue growth of 91.65% for the second quarter of 2023, compared to the same period in 2022. Financial Highlights: Revenue Growth:The second quarter ending June 30, 2023, saw revenues of $431,184, up from $224,986 in 2022. For the six-month period ending June 30, 2023, revenues grew from $680,202 to $922,651, a growth of

Alexandro C. Roamers and 33 Nobel Prize winners Assisi meeting

Source Node:
Time Stamp: June 22, 2023 6:16 AM - Modified On: June 22, 2023 - Published By:
Source Cluster:
Republished By Plato

For the first time in history, 33 Nobel Prize winners and the winner of the last Saint Francis Dassi Award, Alejandro G. Roamers, met to speak to humanity. On June 10, a world meeting was held in the Vatican, initiated by a fund called "Fratelli Totti". The event dealt with the human sister and sisters, its name was "Not Alone" and turned into a day of celebration and unity around the principles of the encyclopedic letter Pratli Totti: "Joining forces to build a more coordinated world". Fratelli Totti Foundation ,

Paribus Vision

Source Node:
Time Stamp: May 27, 2023 11:55 AM - Modified On: May 27, 2023 - Published By:
Source Cluster:
Republished By Plato

For those who missed our announcements on social media, we are thrilled to share the exciting news that our Mainnet v1 will be relaunched on May 31st! The past few weeks have been demanding and challenging, but we couldn’t be happier with our progress. At Paribus, we have always emphasized the importance of security. While we were shocked and saddened by the exploitation of a loophole in our code, we firmly believe in finding the silver lining in every cloud. The steps we’ve taken following this unfortunate incident have made